Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sacubitril/valsartan: a cardiovascular drug with pluripotential actions.

Literature DB >> 30214874

Sacubitril/valsartan: a cardiovascular drug with pluripotential actions.

Steven G Chrysant¹, George S Chrysant².

Abstract

Entities: Chemical

Year: 2018 PMID： 30214874 PMCID： PMC6129836 DOI： 10.21037/cdt.2018.05.10

Source DB: PubMed Journal: Cardiovasc Diagn Ther ISSN： 2223-3652

× No keyword cloud information.

25 in total

1. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study.

Authors: Martin Magnusson; Amra Jujic; Bo Hedblad; Gunnar Engström; Margaretha Persson; Joachim Struck; Nils G Morgenthaler; Peter Nilsson; Christopher Newton-Cheh; Thomas J Wang; Olle Melander
Journal: J Clin Endocrinol Metab Date: 2011-11-23 Impact factor: 5.958

2. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Authors: Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray
Journal: Lancet Date: 2012-08-26 Impact factor: 79.321

3. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.

Authors: Ji-Guang Wang; Kimihiko Yukisada; Antonio Sibulo; Kudsia Hafeez; Yan Jia; Jack Zhang
Journal: J Hypertens Date: 2017-04 Impact factor: 4.844

4. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Authors: Jessie Gu; Adele Noe; Priya Chandra; Suliman Al-Fayoumi; Monica Ligueros-Saylan; Ramesh Sarangapani; Suzanne Maahs; Gary Ksander; Dean F Rigel; Arco Y Jeng; Tsu-Han Lin; Weiyi Zheng; William P Dole
Journal: J Clin Pharmacol Date: 2009-11-23 Impact factor: 3.126

5. Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension.

Authors: J Jordan; R Stinkens; T Jax; S Engeli; E E Blaak; M May; B Havekes; C Schindler; D Albrecht; P Pal; T Heise; G H Goossens; T H Langenickel
Journal: Clin Pharmacol Ther Date: 2016-11-17 Impact factor: 6.875

Review 6. Natriuretic peptides and fat metabolism.

Authors: Cedric Moro
Journal: Curr Opin Clin Nutr Metab Care Date: 2013-11 Impact factor: 4.294

7. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin.

Authors: S Ando; M A Rahman; G C Butler; B L Senn; J S Floras
Journal: Hypertension Date: 1995-12 Impact factor: 10.190

8. Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension.

Authors: Stefan Engeli; Rudi Stinkens; Tim Heise; Marcus May; Gijs H Goossens; Ellen E Blaak; Bas Havekes; Thomas Jax; Diego Albrecht; Parasar Pal; Uwe Tegtbur; Sven Haufe; Thomas H Langenickel; Jens Jordan
Journal: Hypertension Date: 2017-11-27 Impact factor: 10.190

9. The Clinical Significance of N-terminal Pro-brain Natriuretic Peptide in Detecting the Residual Cardiovascular Risk in Hypertension and Other Clinical Conditions and in Predicting Future Cardiovascular Events.

Authors: Steven G Chrysant
Journal: J Clin Hypertens (Greenwich) Date: 2016-02-01 Impact factor: 3.738